How is congenital TTP treated with recombinant ADAMTS13?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18419925
Cited by: 0

Abstract

Recombinant ADAMTS13 appears to be an effective treatment for congenital TTP, offering higher enzyme activity and improved clinical outcomes compared to traditional plasma therapies, though longer-term studies are needed for comprehensive evaluation.

Fields of Study & Subjects

Complement system in diseases Blood Coagulation and Thrombosis Mechanisms Platelet Disorders and Treatments

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
29 January 2026